FDA Approves Regeneron Pharmaceuticals' Higher Dose Of Eylea For Age-Related Blindness
Portfolio Pulse from Vandana Singh
The FDA has approved Regeneron Pharmaceuticals' Eylea HD Injection 8 mg for wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy. The approval is based on the results of two pivotal trials, PULSAR and PHOTON. Regeneron and Bayer AG are jointly developing Eylea HD, which is priced at $2,625 per single-use vial in the U.S.
August 21, 2023 | 12:37 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Bayer AG, jointly developing Eylea HD with Regeneron, could see a positive impact on its stock.
As a partner in the development of Eylea HD, Bayer AG could also benefit from the FDA approval in terms of investor confidence and potential stock price increase.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 50
POSITIVE IMPACT
Bayer AG, jointly developing Eylea HD with Regeneron, could see a positive impact on its stock.
As a partner in the development of Eylea HD, Bayer AG could also benefit from the FDA approval in terms of investor confidence and potential stock price increase.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 50
POSITIVE IMPACT
FDA approval of Eylea HD Injection 8 mg could boost Regeneron's stock in the short term.
FDA approval of a new drug typically leads to increased investor confidence and a potential rise in the company's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100